News
NAMSW
25.20
-7.69%
-2.10
Weekly Report: what happened at NAMSW last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at NAMSW last week (1117-1121)?
Weekly Report · 11/24 09:49
Weekly Report: what happened at NAMSW last week (1110-1114)?
Weekly Report · 11/17 09:49
NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating
Seeking Alpha · 11/16 15:30
Weekly Report: what happened at NAMSW last week (1103-1107)?
Weekly Report · 11/10 09:47
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 11/07 15:01
Weekly Report: what happened at NAMSW last week (1027-1031)?
Weekly Report · 11/03 09:46
Weekly Report: what happened at NAMSW last week (1020-1024)?
Weekly Report · 10/27 09:49
Weekly Report: what happened at NAMSW last week (1013-1017)?
Weekly Report · 10/20 09:47
Weekly Report: what happened at NAMSW last week (1006-1010)?
Weekly Report · 10/13 09:49
Weekly Report: what happened at NAMSW last week (0929-1003)?
Weekly Report · 10/06 09:47
Weekly Report: what happened at NAMSW last week (0922-0926)?
Weekly Report · 09/29 09:47
Weekly Report: what happened at NAMSW last week (0915-0919)?
Weekly Report · 09/22 09:47
Weekly Report: what happened at NAMSW last week (0908-0912)?
Weekly Report · 09/15 11:05
Weekly Report: what happened at NAMSW last week (0901-0905)?
Weekly Report · 09/08 11:07
Weekly Report: what happened at NAMSW last week (0825-0829)?
Weekly Report · 09/01 11:03
Weekly Report: what happened at NAMSW last week (0818-0822)?
Weekly Report · 08/25 11:13
Weekly Report: what happened at NAMSW last week (0811-0815)?
Weekly Report · 08/18 11:05
Silence Therapeutics Announces Board Resignation and Appointment Changes
Reuters · 08/14 10:31
Weekly Report: what happened at NAMSW last week (0804-0808)?
Weekly Report · 08/11 11:12
More
Webull provides a variety of real-time NAMSW stock news. You can receive the latest news about NewAmsterdam Pha through multiple platforms. This information may help you make smarter investment decisions.
About NAMSW
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.